EXHIBIT 2 

Case 1:20-mj-03050-AOR Document 7-2 Entered on FLSD Docket 07/08/2020 Page 1 of 7
UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF FLORIDA

CASE NO: 1:20CV21601

UNITED STATES OF AMERICA,

Plaintiff,

vs.

GENESIS II CHURCH OF HEALTH

AND HEALING,

MARK GRENON,

JOSEPH GRENON,

JORDAN GRENON, and

JONATHAN GRENON,

Defendants.

____________________________________/

SEALED TEMPORARY RESTRAINING ORDER

1. Plaintiff has filed a Complaint for Injunction against Genesis II Church 

of Health and Healing (“Genesis”), and Mark Grenon, Joseph Grenon, Jordan 

Grenon, and Jonathan Grenon, individuals (collectively, “Defendants”), pursuant 

to the Federal Food, Drug, and Cosmetic Act (“FDCA”), 21 U.S.C. § 332(a), and 

the inherent equitable authority of this Court, alleging that Defendants directly or 

indirectly do or cause the following acts:

A. Violate 21 U.S.C. § 331(d), by introducing or delivering for 

introduction into interstate commerce new drugs, as defined in 21 U.S.C. § 321(p), 

that are neither approved pursuant to 21 U.S.C. § 355 nor exempt from approval;

Case 1:20-mj-03050-AOR Document 7-2 Entered on FLSD Docket 07/08/2020 Page 2 of 7 Case 1:20-cv-21601-KMW Document 4 Entered on FLSD Docket 04/17/2020 Page 1 of 6
2

B. Violate 21 U.S.C. § 331(a), by introducing or delivering for 

introduction into interstate commerce drugs, as defined in 21 U.S.C. § 321(g), that 

are misbranded within the meaning of 21 U.S.C. § 352(a) and (f)(1); and

C. Violate 21 U.S.C. § 331(k), by causing drugs to become 

misbranded within the meaning of 21 U.S.C. § 352(a) and (f)(1) while they are held 

for sale after shipment of one or more of their components in interstate commerce.

2. This Court has jurisdiction over the subject matter and Defendants.

3. The Complaint for Injunction alleges a cause of action against 

Defendants under the FDCA.

4. The United States has demonstrated that Defendants are violating 

the FDCA, 21 U.S.C. § 301, et seq. and that there is a cognizable danger that 

Defendants will continue so in the future unless a temporary restraining order is 

issued.

5. Because the United States’ motion is based upon 21 U.S.C. § 332(a), 

which expressly authorizes injunctive relief to protect the public interest, no specific 

finding of irreparable harm is necessary, no showing of any inadequacy of other 

remedies at law is necessary and no balancing of interests of the parties is required 

prior to the issuance of a temporary restraining order in this case.

6. The provision of advance notice to Defendants is not required 

because the immediate and irreparable injury to public health may result before 

Defendants may be heard. 

Case 1:20-mj-03050-AOR Document 7-2 Entered on FLSD Docket 07/08/2020 Page 3 of 7 Case 1:20-cv-21601-KMW Document 4 Entered on FLSD Docket 04/17/2020 Page 2 of 6
3

7. The conditions for granting a temporary restraining order under Rule 

65(b) of the Federal Rules of Civil Procedure and 21 U.S.C. § 332(a) having thus 

been met.

After considering the foregoing, it is therefore,

ORDERED, ADJUDGED AND DECREED that:

1. The United States’ Motion for a Temporary Restraining Order is GRANTED 

without notice to Defendants. Pursuant to Federal Rule of Civil Procedure 65(b)(2), 

this Temporary Restraining Order was issued on April 17th, 2020, at 10:00AM. 

This Temporary Restraining Order shall expire on May 1, 2020 at 10:00 AM, unless 

it is extended by the Court for good cause shown or the Defendants consent to a 

longer extension.

2. Upon entry of this Order, Defendants and each and all of their directors, 

officers, agents, representatives, employees, successors, assigns, attorneys, and 

any and all persons in active concert or participation with any of them 

(hereinafter, “Associated Persons”) who receive actual notice of this Order, shall 

not, during the pendency of this action, directly or indirectly, label, hold, and/or 

distribute any drug, including but not limited to MMS, that does not have an 

approved new drug application pursuant to 21 U.S.C. § 355(b) or abbreviated 

new drug application pursuant to 21 U.S.C. § 355(j), or an investigational new 

drug application in effect for its use pursuant to 21 U.S.C. § 355(i), or any drug 

that is misbranded within the meaning of 21 U.S.C. § 352.

Case 1:20-mj-03050-AOR Document 7-2 Entered on FLSD Docket 07/08/2020 Page 4 of 7 Case 1:20-cv-21601-KMW Document 4 Entered on FLSD Docket 04/17/2020 Page 3 of 6
4

3. Upon entry of this Order, Defendants and Associated Persons, shall not, 

directly or indirectly, violate 21 U.S.C. § 331(k) by causing any drug, including but 

not limited to MMS, to become misbranded within the meaning of 21 U.S.C. 

§ 352(a) and/or (f)(1) after shipment of one or more of its components in interstate 

commerce.

4. Upon entry of this Order, Defendants and Associated Persons shall 

immediately refrain from disposing of or transferring any assets that may interfere 

with implementation of payment of restitution to consumers who purchased 

Defendants’ drugs, should the Court ultimately order such restitution payments in 

its final judgment in this matter.

5. Upon entry of this Order, Defendants and Associated Persons are 

prohibited from destroying, discarding, altering, transferring or otherwise making 

unavailable any document or record in electronic format or otherwise within their 

custody or control that are related to (a) MMS; (b) misbranded drugs; and/or (c) 

unapproved new drugs.

6. Representatives of FDA shall be permitted, without prior notice and as and 

when FDA deems necessary, to inspect Defendants’ places of business and take 

any other measures necessary to monitor and ensure continuing compliance with 

the terms of this Order. During such inspections, FDA representatives shall be 

permitted to: have immediate access to buildings, including but not limited to 2014 

Garden Ln, Bradenton, FL 34205-5274 (the “Facility”), equipment, raw ingredients, 

in-process materials, finished products, containers, packaging material, labeling, 

Case 1:20-mj-03050-AOR Document 7-2 Entered on FLSD Docket 07/08/2020 Page 5 of 7 Case 1:20-cv-21601-KMW Document 4 Entered on FLSD Docket 04/17/2020 Page 4 of 6
5

and other promotional material therein; take photographs and make video 

recordings; take samples of Defendants’ in-process or unfinished and finished 

products, containers, packaging material, labeling, and other promotional material; 

and examine and copy all records relating to the labeling, holding, and distribution 

of any and all drugs and their components. The inspections shall be permitted upon 

presentation of a copy of this Order and appropriate credentials. The inspection 

authority granted by this Order is separate and apart from, and in addition to, the 

authority to make inspections under the FDCA, 21 U.S.C. § 374.

7. Defendants shall bear the cost of any inspections, analytical work, and 

supervisory activities that FDA deems necessary to evaluate Defendants’ 

compliance with any of the terms of this Order.

8. Defendants shall post a copy of this Order in a common area at the Facility 

and at any other location at which Defendants conduct business and shall ensure 

that the Order remains posted for as long as the Order remains in effect.

9. IT IS FURTHER ORDERED that the United States shall promptly provide 

notice of this action and this Order to Defendants by, to the extent necessary, 

attempting service at last known email addresses and physical addresses. 

Pursuant Rule 65(c) of the Federal Rules of Civil Procedure, Plaintiff United 

States of America shall not be required to post security for the instant action.

10. This matter is set for a preliminary injunction hearing on Friday, May 1, 

2020, at 10:00AM. 

DONE AND ORDERED in chambers in Miami, Florida, this 17th day of April, 2020.

Case 1:20-mj-03050-AOR Document 7-2 Entered on FLSD Docket 07/08/2020 Page 6 of 7 Case 1:20-cv-21601-KMW Document 4 Entered on FLSD Docket 04/17/2020 Page 5 of 6
6

Case 1:20-mj-03050-AOR Document 7-2 Entered on FLSD Docket 07/08/2020 Page 7 of 7 Case 1:20-cv-21601-KMW Document 4 Entered on FLSD Docket 04/17/2020 Page 6 of 6